Prescription Patterns of Non-Vitamin K Oral Anticoagulants Across Indications and Factors Associated with Their Increased Prescribing in Atrial Fibrillation Between 2012-2015: A Study from the Norwegian Prescription Database
| Autor: | Bjorn Oddvar Strøm, Anna Maria Urbaniak, Kristin Helene Svanqvist, Randi I. Krontveit |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty Databases Factual Deep vein Administration Oral 030204 cardiovascular system & hematology Drug Prescriptions 03 medical and health sciences 0302 clinical medicine Thromboembolism Atrial Fibrillation medicine Humans Pharmacology (medical) 030212 general & internal medicine Medical prescription Practice Patterns Physicians' Aged Aged 80 and over Rivaroxaban business.industry Norway Warfarin Anticoagulants Atrial fibrillation Middle Aged medicine.disease Thrombosis Pulmonary embolism medicine.anatomical_structure Apixaban Female Geriatrics and Gerontology business medicine.drug |
| Zdroj: | Drugsaging. 34(8) |
| ISSN: | 1179-1969 |
| Popis: | We studied prescription patterns for non-vitamin K oral anticoagulants (NOACs) in Norway between 2012 and 2015, and compared NOAC and warfarin patient characteristics such as age, gender and cardiovascular (CV) co-medications across reimbursed indications. Factors associated with NOAC prescribing in atrial fibrillation (AF) were also analysed.All Norwegian patients (N = 156,124) who received at least one dispensed NOAC or warfarin prescription within the indications of AF, deep vein thrombosis and pulmonary embolism (DVT_PE) or prevention of venous thromboembolic events after a hip or knee surgery (VTE_surg) between 2012 and 2015 were included in the study. Descriptive statistics was applied to compare patient characteristics between NOACs and warfarin across indications and a logistic regression model was used to identify factors associated with NOAC prescribing in AF.NOACs and warfarin were most commonly prescribed in AF (83,729 patients in 2015), followed by DVT_PE (16,077 patients) and lastly in VTE_surg (4060 patients). In 2015, NOACs achieved a dominant (50%) patient share over warfarin in AF and DVT_PE, and were prescribed in 80% of new oral anticoagulation (OAC) patients. Apixaban, despite its delayed market entry, emerged as the preferred NOAC in VTE_surg (46% share), whereas rivaroxaban captured a 43% patient share in DVT_PE. Warfarin patients were on average older and received more CV co-medication than NOAC patients in AF and DVT_PE. Age, gender and certain CV co-medications emerged as significant predictors of NOAC prescribing in AF. AF patients70 years old had higher odds of NOAC prescribing (OR 1.19-1.29, depending on age category), in contrast to patients74 years old (OR 0.51-0.77). Women had 32% higher odds of receiving a NOAC in AF.NOACs achieved a dominant market share over warfarin within 3 years from receiving reimbursement in Norway. There were significant differences in patient characteristics between drugs and indications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink